Companies Dominating the Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Astellas Pharma Inc.
- Clovis Oncology, Inc.
- Johnson & Johnson Health Care Systems Inc.
- Bayer AG
- Orion Corporation
- Merck & Co., Inc.
- Novartis AG
- AstraZeneca PLC
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of non-metastatic castration resistant prostate cancer treatment is estimated at USD 8.28 billion.
The non-metastatic castration resistant prostate cancer treatment market size was valued at USD 7.68 billion in 2024 and is likely to cross USD 14.13 billion by 2037, expanding at more than 4.8% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of prostate cancer and growth in the investment and R&D activities in oncology will boost the market growth.
North America industry is anticipated to dominate majority revenue share of 30% by 2037, propelled by increasing awareness about nmCRPC and the need to develop innovative cancer treatment solutions in the region.
The major players in the market are Pfizer Inc., Astellas Pharma Inc., Clovis Oncology, Inc., Johnson & Johnson Health Care Systems Inc., Bayer AG, Orion Corporation, Merck & Co., Inc., Novartis AG, AstraZeneca PLC
